Roivant Sciences shares surge 20.84% after-hours on positive Phase 2 results for brepocitinib in cutaneous sarcoidosis.

Roivant Sciences surged 20.84% in after-hours trading following the release of positive Phase II results for brepocitinib in cutaneous sarcoidosis, a condition with no approved therapies. The trial demonstrated 100% of patients on the 45 mg dose achieving ≥10-point improvement in the CSAMI score, with 62% reaching functional remission, alongside a strong safety profile. These results, highlighted during the Q3 earnings call, reinforced Roivant’s pipeline momentum, including an NDA filing for brepocitinib in dermatomyositis and plans for a Phase III trial in cutaneous sarcoidosis in 2026. The stock’s sharp rise aligned with media reports describing the data as “exceptional,” underscoring investor optimism about the drug’s potential to address unmet medical needs and advance Roivant’s near-term clinical and regulatory milestones.